The site will be unavailable from 11:00 PM GMT on Tuesday, 21 July 2026, until 4:00 AM GMT on Wednesday, 22 July 2026, due to scheduled maintenance.

This Plain Language Summary Publication from Future Oncology describes the results from a study called CheckMate 274 which looked at a new medication called nivolumab and how well it worked to reduce the chance of muscle-invasive urothelial cancer returning after surgery.

Read the full article here

The original article on which this Plain Language Summary of Publication is based is titled ‘Adjuvant Nivolumab versus Placebo in Muscle-Invasive Urothelial Carcinoma’ and was published in The New England Journal of Medicine. Read the original article here.